Please login to the form below
TYK2 inhibitor
This page shows the latest TYK2 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
Takeda has announced positive phase 2b results for its investigational TYK2 inhibitor, TAK-279, in patients with moderate-to-severe plaque psoriasis. ... selective TYK2 inhibition to provide an effective and convenient oral treatment option for people
Latest news
-
Takeda to acquire Nimbus’ TYK2 inhibitor in deal worth $6bn
Takeda has announced it will acquire Nimbus Therapeutics' NDI-034858, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases, in a deal ... margins. NDI-034858 is a potentially
-
UPDATED: BMS completes Celgene merger after FTC okay
overlap with BMS’ TYK2 inhibitor BMS-986165 could give the combined company an overly-dominant position in the market. ... Otezla slots nicely into Amgen’s existing psoriasis and anti-inflammatory portfolio, which includes TNF inhibitor Enbrel
-
Amgen snaps up Celgene’s Otezla for $13.4bn
2 (TYK2) inhibitor would give too big a share of the market.
-
Otezla scores new indication as speculation over potential buyers grows
The FTC pointed to Otezla and a BMS pipeline candidate in the therapy area, a tyrosine kinase 2 (TYK2) inhibitor, as the reason for these concerns.
-
Faced with regulator’s merger concerns, BMS want to offload Otezla
The regulator has pointed to BMS’ pipeline candidate in the therapy area, a tyrosine kinase 2 (TYK2) inhibitor, which it has indicated that in combination with Celgene's Otezla could give
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Today, some of the most innovative therapies in development are Janus kinase (JAK) inhibitors, and the latest ‘game changer’ Tyrosine kinase 2 (TYK2) inhibitors. ... The healthcare press has described TYK2 inhibitors as having the potential
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
